Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
10/18/2025
-
MarketBeat
3/16/2026
-
TipRanks Financial Blog
3/16/2026
-
MarketBeat
3/16/2026
-
MarketBeat
3/15/2026
-
MarketBeat
3/15/2026
-
MarketBeat
3/14/2026
-
MarketBeat
3/12/2026
-
Seeking Alpha: Transcripts
3/12/2026
-
SeekingAlpha
3/12/2026
-
Tickeron - Stocks
3/11/2026
-
Tickeron - Stocks
3/11/2026
-
MarketBeat
3/9/2026
-
MarketBeat
3/8/2026
-
Insider Monkey
Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)?
3/8/2026
-
Simply Wall St
3/7/2026
-
MarketBeat
3/7/2026
-
MarketBeat
3/6/2026
-
Tickeron - Stocks
3/5/2026
-
Simply Wall St
3/5/2026
-
Tickeron - Stocks
3/4/2026
-
Simply Wall St
3/4/2026
-
MarketBeat
3/4/2026
-
Tickeron - Stocks
3/3/2026
-
MarketBeat
3/3/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, February 25, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
510 474 0170
Address
7707 Gateway Boulevard
Newark, CA 94560
Newark, CA 94560
Country
Year Founded
Business Description
Sector
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment...
more